Lunai Bioworks shares rise 71.56% intraday after acquiring CNS drug assets from Clemann Group in $20M strategic deal.

Lunai Bioworks surged 71.56% in intraday trading, as the clinical-stage biotechnology company executed a $20 million strategic transaction to acquire the Clemann Group's blood-brain barrier delivery technology and CNS Alzheimer's drug assets at a fixed conversion price of $1.50 per share to address critical bottlenecks in CNS drug development.